Screener
Discontinued — last reported Q2 '26
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001299130-26-000122
| (In thousands, except per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total cost of revenue | 26,369 | 25,082 | 50,706 | 63,606 |
| Gross profit | 12,638 | 14,684 | 25,479 | 13,313 |
| Operating Expense: | ||||
| Research and development | 23,022 | 22,529 | 42,630 | 51,582 |
| Sales, general and administrative | 33,393 | 36,175 | 64,546 | 76,343 |
| Impairment charges | — | — | — | 15,000 |
| Settlement charges | — | — | 15,400 | — |
| Gain on disposal of assets | — | — | (45,796) | — |
Item 1. Financial Statements (unaudited):
FAQ
- What is Pacific Biosciences of California's R&D?
- Pacific Biosciences of California (PACB) reported R&D of $23.02M in Q2 2026.
- How has Pacific Biosciences of California's R&D changed year-over-year?
- Pacific Biosciences of California's R&D increased by 2.2% year-over-year, from $22.53M to $23.02M.
- What is the long-term trend for Pacific Biosciences of California's R&D?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's R&D has grown at a -3.6% compound annual growth rate (CAGR), from $112.9M to $97.31M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Pacific Biosciences of California's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude